Key Drivers
- Margin Compression
- Cash Burn
- Higher Leverage
AIAI Summary
ALKS has shifted from a stable psychiatry cash-generating compounder to a more binary, execution-driven neuroscience story, with Q1 2026's margin, cash flow, and net-debt deterioration making success on alixorexton, LUMRYZ expansion, and Avadel integration the key determinant of whether the recent rally is justified or overextended.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Cash Burn
- •Higher Leverage
ALKS' strong FY2025 profitability and cash generation deteriorated sharply in Q1 2026 as operating costs surged, cash flow turned negative, and leverage rose materially despite still-healthy liquidity.
Price Behavior
Key Price Behavior Insights:
- •Breakout Hold
- •Strong Momentum
- •Near-Term Extension
ALKS has trended strongly higher over the last month, holding its breakout in the low-50s, but it now looks extended near $55 resistance and may need consolidation before a further move.
Fast run from the low-$40s into the mid-$50s raises short-term pullback risk
Sentiment & News
Key News Insights:
- •Trial success
- •Orphan designations
- •Deal integration
Alkermes is gaining momentum as positive alixorexton trial results, orphan-drug designations, and Avadel integration progress strengthen its sleep-disorder pipeline and investor outlook.
This news is likely supportive for ALKS, as clinical validation and regulatory recognition may continue to drive sentiment and rerating potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings